



## **SINCLAIR PHARMA PLC**

### **Decapinol® licensing deal in Israel**

#### **Three new licensing agreements in North America and three in Colombia Xclair™, Salinum™ and SST™**

**Godalming UK, 29 June, 2005:** Sinclair Pharma plc ("Sinclair" or the "Company") (SPH.L), the specialty pharmaceutical company, today announces a new licensing agreement for Decapinol®, the company's oral rinse for the treatment and prevention of gingivitis, which is currently approved in the EU and which recently received US FDA approval. Sinclair also announces the signing of a further three licensing agreements in North America (US and Canada) and three in Colombia.

Under the terms of the Decapinol® agreement, the product has been exclusively licensed for ten years to Kivema Ltd. ("Kivema") for distribution in Israel. Kivema specialises in oral care, dermatology and ophthalmology and has full coverage of the retail Pharma trade across Israel as well as direct access to over 1000 dental clinics.

Sinclair are pleased to announce that they have appointed Align Pharmaceuticals as licensees in North America (US and Canada) on ten year exclusive contracts for the three products below. Align is a new US company with strong venture capital funding, specialised in radiation oncology, dental and rheumatology products. The company will target the US market via a combination of contract salespeople and co-promotion partners who will have over 100 sales representatives selling the following products.

In addition Sinclair announce that the same three products have been licensed exclusively in Colombia to Bio Pharma, a company representing major pharma companies such as Abbott, Novartis and Zambon.

The products licensed to Align and Bio Pharma are:

**Xclair™** for the treatment of radiation dermatitis;

#### **Salinum™**

Salinum™ is Sinclair's saliva replacement product for the treatment of dry mouth syndrome, ("xerostomia") where the salivary glands are able to produce little or no saliva.

#### **SST™**

SST™ is Sinclair's saliva stimulating tablet for the treatment of milder forms of dry mouth syndrome.

Dr Michael Flynn, CEO of Sinclair, said: "The licensing deal in Israel is a further advancement of our international commercialisation strategy for Decapinol®. We believe that a good efficacy profile and high level of patient acceptance of Decapinol® provides very significant patient benefits and expect the product to rapidly gain market acceptance with each new territory launch.

We are also very pleased to have signed up Align and Bio Pharma as licensees for Xclair™, Salinum™ and SST™. In so doing we are following our strategy of licensing our products to distributors whom we believe will best promote our products in their territories."

**Enquiries:****Sinclair Pharma plc**

Dr Michael Flynn, CEO  
John Barrington-Carver (Corporate PR)

Tel: 01483 426 6444  
Tel: 07831 655 630

**Financial Dynamics**

Lucy Briggs

Tel: 0207 269 7242

[www.sinclairpharma.com](http://www.sinclairpharma.com)

**Notes to editors:****Sinclair Pharma plc**

**Sinclair Pharma plc** based in Godalming in the UK, is quoted on the Alternative Investment Market (AIM) on the London Stock Exchange and has focused on the acquisition and development of niche patented pharmaceutical products in the fields of oral health, oncology support and dermatology, and bringing them to the international market place via out-licensing partners. The Company combines product evaluation, product development, regulatory and business development expertise to add value to its acquired and in-house developed products. A key element of the Sinclair business model is to minimise risk and exposure by avoiding involvement in lengthy R&D programmes and rapidly achieving global distribution through a network of marketing partners. The Company has already licensed its products for distribution in over 40 countries around the world.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward- looking statements due to a variety of factors.